CYP19A1 and breast carcinoma: Despite the development of different targeted therapies to treat ER+ breast cancer patients, such as tamoxifen, fulvestrant, or aromatase inhibitors [14,17], 15–20% of patients still relapse within 5 years of treatment withdrawal [50].